LAUSR

Pharma/Astra Zeneca, Celgene. Janssen; Honoraria: Abbvie, Acerta Pharma/Astra Zeneca, Celgene. Janssen, Gilead Sciences, Roche/Genentech, TG Therapeutics; Research Funding: Acerta Pharma/Astra Zeneca, Janssen, Celgene. Trneny, M: Consultant Advisory Role: Takeda, BMS, Incyte, Abbvie, Amgen, Roche, Gilead, Janssen, Celgene, MorphoSys; Honoraria: Janssen, Gilead, Takesa, BMS, Amgen, Abbvie, Roche, MorphoSys, Incyte; Other Remuneration: Travel & Expenses: Gilead, Takeda, BMS, Roche, Janssen, Abbvie. Izutsu, K: Consultant Advisory Role: Eisai, MSD, Takeda, Ono, AstraZeneca, Abbvie, Bayer, Novartis, Chugai, Daiichi Sankyo, Otsuka; Honoraria: Kyowa Hakko Kirin, Eisai, MSD, Takeda, Janssen, Dainippon Sumitomo, Mundipharma, Nihon Mediphysics, Abbvie, Chugai, Zenyaku, Bristol Myers Squib, Astellas; Research Funding: HUYA bioscience, MSD, Astellas Amgen, AstraZeneca, Abbvie, Eisai, Ono, Sanofi, ARIAD, Symbio, Zenyaku, Celgene, Solaisia, Takeda, Daiichi Sankyo, Chugai, Novarsis, Bayer, Pfizer. Fowler, N: Consultant Advisory Role: Roche/Genentech, TG Therapeutics, Verastem, Bayer, Celgene, Novartis; Research Funding: Roche, Celgene, Gilead Sciences, TG Therapeutics, Novartis, Abbvie, BeiGene. Nowakowski, G: Consultant Advisory Role: (author's institution for all) Celgene, MorphoSys, Genentech; Research Funding: (author's institution for all) Celgene, NanoString Technologies, MorphoSys. Pinto, A: Consultant Advisory Role: Servier, Roche, MDS Pharma, BMS; Honoraria: Roche, MDS Pharma, Celgene, BMS; Other Remuneration: Speakers' Bureau: Roche; Patents, Royalties or Intellectual Property: EDOMundipharma; Travel: Roche, Takeda. Scheinberg, P: Consultant Advisory Role: Novartis, Abbvie, Alexion Pharmaceuticals, Janssen, Celgene; Honoraria: Novartis; Other Remuneration: Speakers' Bureau: Novartis, Pfizer. Flinn, I: Consultant Advisory Role: (All instituional): Abbvie, Seattle Genetics, TG Therapeutics, Verastem; Research Funding: (All institutional): Acerta Pharma, Agios, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Genentech, Gilead Sciences, Incyte, Infinity Pharmaceuticals, Janssen, Karyopharm Therapeutics, Kite Pharma, Novartis, Pharmacyclics, Portola Pharmaceuticals, Roche, TG Therapeutics, Trillium Therapeutics, Abbvie, ArQule, BeiGene, Curis, FORMA Therapeutics, Forty Seven, Merck, Pfizer, Takeda, Teva, Verastem, Gilead Sciences, Astra Zeneca (AZ), Juno Therapeutics, Unum Therapeutics, MorphoSys AG, Abbvie. Czuczman, M: Employment Leadership Position: Celgene; Stock Ownership: Celgene. Kalambakas, S: Employment Leadership Position: Celgene; Stock Ownership: Celgene. Fustier, P: Employment Leadership Position: Celgene; Stock Ownership: Celgene. Wu, C: Employment Leadership Position: Celgene; Stock Ownership: Celgene. Leonard, J: Consultant Advisory Role: Celgene, Biotest, Sunesis Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Epizyme, Pfizer, Bayer, Genentech/Roche, ADC Therapeutics, MEI Pharma, AstraZeneca, Novartis, Merck, Sutter Medical Group, Morphosys, Beigene, Nordic Nanovector, Bristol-Myers Squibb, United Therapeutics, Karyopharm Therapeutics, Sand; Research Funding: (all institutional): Celgene, Alliance for Clinical Trials in Oncology, Takeda, Pfizer, National Cancer Institute; Other Remuneration: Travel, Accommodation, Expenses: BeiGene. 179 EFFICACY AND SAFETY OF PROLONGED MAINTENANCE WITH SUBCUTANEOUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT NHL: RESULTS OF THE PHASE III MABCUTE STUDY S. Rule | W.G. Barreto | J. Briones | A.M. Carella | O. Casasnovas | C. Pocock | C.M. Wendtner | F. Zaja | S. Robson | R.R. Tschopp | M. Dreyling Department of Haematology, Derriford Hospital and Plymouth University Medical School, Plymouth, United Kingdom; Hematology and Hemotherapy, Hemocentro Ribeirão Preto, University of São Paulo, São Paulo, Brazil; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Division of Hematology and Stem Cell Transplantation Unit, L'Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliera Universitaria "San Martino" – Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; Service d'Hématologie Clinique, Centre Hospitalier Universitaire François Mitterand, Dijon, France; Department of Haematology, Kent & Canterbury Hospital, Canterbury, United Kingdom; Department I of Internal Medicine, Klinikum Schwabing, Munich, Germany; SC Ematologia, Azienda Sanitaria Universitaria Integrata di Trieste, Trieste, Italy; Product Development Medical Affairs, Biometrics, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Product Development Medical Affairs, Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; Department of Medicine III, Klinikum der Universität München (LMU), Munich, Germany